Author

D. Araiza-Olivera

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Uribe-Alvarez· 3 shared J. Chernoff· 3 shared A. M. Kurimchak· 2 shared J. S. Duncan· 2 shared K. Q. Cai· 2 shared A. C. Cannon· 1 shared A. Cannon· 1 shared C. Herrera-Montavez· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Uribe-Alvarez

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Identifying and targeting key driver genes for collagen production within the 11q13/14 breast cancer amplicon

D. Araiza-Olivera, T. Y. Prudnikova, C. Uribe-Alvarez, K. Q. Cai, J. Franco-Barraza, J. M. Dones, R. Raines, J. Chernoff

This study identifies P4HA3 and SERPINH1 as key driver genes for collagen production in IntClust-2 breast cancer, showing their role in cell viability, proliferation, and migration, and demonstrates that targeting these genes can reduce tumor growth.

bioRxiv · Mar 27, 2024Cancer Biology

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

A. C. Cannon, K. Budagyan, C. Uribe-Alvarez, A. M. Kurimchak, D. Araiza-Olivera, K. Q. Cai, S. Peri, Y. Zhou, J. S. Duncan, J. Chernoff

This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

A. M. Kurimchak, C. Herrera-Montavez, S. Montserrat-Sangra, D. Araiza-Olivera, J. Hu, J. Jin, J. S. Duncan

This study identifies MDR1 as a mediator of resistance to PROTACs in cancer cells and shows that combining MDR1 inhibitors with PROTACs enhances drug efficacy.

bioRxiv · Dec 2, 2021Cancer Biology

Targeting effector pathways in RAC1P29S-driven malignant melanoma

C. Uribe-Alvarez, S. L. Guerrero-Rodriguez, J. Rhodes, A. Cannon, J. Chernoff, D. Araiza-Olivera

This study investigates the efficacy of targeting effector pathways of RAC1P29S in melanoma, showing that PAK and SRF/MRTF inhibitors reduce tumor growth in vitro and in zebrafish models.

bioRxiv · Aug 28, 2019Cancer Biology